Takeda Publishes the Results of Livtencity (maribavir) in P-III (SOLSTICE) Trial for Post-Transplant Patients with Cytomegalovirus Infection in CID
Shots:
- The P-III (SOLSTICE) trial evaluates Livtencity (400 mg, bid) vs conventional antiviral therapy in a ratio (2:1) in 352 HCT & SOT recipients with CMV infection refractory with/out resistance to one or a combination of conventional antiviral therapies
- The trial meet its 1EPs & 2EPs i.e., patients achieved 55.7% (131/235) vs 23.9% (28/117) confirmed CMV DNA level @8wks., symptom control @8wks. & maintained @16wks., higher proportion of patients meet the EPs (18.7%, 44/235) vs (10.3%, 12/117); treatment discontinuation due to AEs (13%, 31/234 vs 32%, 37/116)
- Livtencity is an orally bioavailable anti-CMV compound & 1st antiviral agent that target pUL97 protein kinase & natural substrates
Ref: Takeda | Image: Takeda
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com